No abstract

No abstract

No abstract

10642 Background: Our aim was to assess the efficacy and tolerability of paclitaxel combined with cisplatin in the treatment of MBC patients previously treated with anthracyclines either as adjuvant treatment or as first-line chemotherapy for MBC. Methods: The study included 168 patients divided in two groups: 64 patients in group I who received adjuvant FAC and 104 patients in group II who received CMF as adjuvant therapy and FAC for MBC as first-line treatment. Participants received paclitaxel 90 mg/m2 on day 1 and cisplatin 60 mg/m2 on day 2 q/2w. Total number of cycles per patient was 3–9. Results: Evaluation was made after 3 cycles of chemotherapy. Obtained RR was: in group I, CR in 4 (6.26%), PR in 30 (46.87%), SD in 5 (7.81%), and PD in 25 (39.06%) patients, with ORR in 34 (53.13%) patients. In group II, the obtained results were: CR in 3 (2.88%), PR in 36 (34.6%), SD in 6 (5.77%), and PD in 59 (56.75%) patients, with ORR in 39 (37.49%) patients. Patients with CR received 3 more cycles and patients with PR received 3 or 6 therapies depending on the obtained results. Treatment evaluation of PR patients in group I after cycle 6 resulted with CR only in 1 (1.56%) patient and in group II showed CR in 2 (1.92%) patients. In those patients 3 more therapies were applied. Difference between the two groups in ORR is highly significant: p < 0.04. Hematological toxicity grades 3 and 4 in both groups were rare and similar. Conclusions: The application of biweekly paclitaxel combined with cisplatin in our patients’ population is efficacious with good tolerability. In group I the obtained results in ORR was 53.13%, which is statistically significantly (p < 0.04) better than in group II with ORR: 37.49%. No significant financial relationships to disclose.

No abstract